Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Appropriate definition of non-metastatic castration-resistant prostate cancer (nmCRPC) and optimal timing of androgen receptor signaling inhibitor (ARSI) ; volume:29 ; number:8 ; day:10 ; month:6 ; year:2024 ; pages:1198-1203 ; date:8.2024
International journal of clinical oncology ; 29, Heft 8 (10.6.2024), 1198-1203, 8.2024
- Creator
-
Matsumoto, Kazuhiro
Kosaka, Takeo
Takeda, Toshikazu
Fukumoto, Keishiro
Yasumizu, Yota
Tanaka, Nobuyuki
Morita, Shinya
Mizuno, Ryuichi
Asanuma, Hiroshi
Oya, Mototsugu
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10147-024-02549-5
- URN
-
urn:nbn:de:101:1-2410102103164.474862872095
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Matsumoto, Kazuhiro
- Kosaka, Takeo
- Takeda, Toshikazu
- Fukumoto, Keishiro
- Yasumizu, Yota
- Tanaka, Nobuyuki
- Morita, Shinya
- Mizuno, Ryuichi
- Asanuma, Hiroshi
- Oya, Mototsugu
- SpringerLink (Online service)
Other Objects (12)
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison
Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison
Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study
The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison
Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
Analysis of regulation of angiogenesis by androgen receptor ligands in castration-resistant prostate cancer
PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer